In a real-world study, patients with psoriatic disease treated with an IL-17 targeted biologic and a GLP-1 agonist ...

GLP-1 RA use is associated with improved survival and lower hospitalization rates in patients with type 2 diabetes receiving cancer therapy.

HealthDay News — Glucagon-like peptide-1 receptor agonist (GLP-1 RA) use is associated with a reduced risk for colorectal ...

Most patients receiving a GLP-1 receptor agonist (RA) and a biologic continue co-therapy for over a year with few treatment-related adverse events.

This randomized controlled trial shows that structured moderate-to-vigorous exercise, alone or combined with liraglutide, ...

Although both sodium-glucose cotransporter-2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) ...

FDA requests removal of suicidal ideation warnings from GLP-1 RA labels after meta-analysis shows no increased risk compared with placebo.

Real-world data analysis suggests that families with at least one member using Novo Nordisk's GLP‑1 RA for weight management tend to reduce spending on alcohol and cigarettes. JAKARTA, Indonesia, Jan.

BEIJING, Nov. 27, 2025 /PRNewswire/ -- Gan & Lee Pharmaceuticals (Gan & Lee, stock code: 603087.SH) announced the initiation of GRADUAL-3, its third large-scale phase 3 clinical study of the ...

GLP-1RA use improves major cardiovascular and kidney outcomes among patients with systemic lupus erythematosus and lupus nephritis. Use of glucagon-like peptide-1 receptor agonists (GLP-1RAs) is ...

Association persisted after removing patients with previous diagnosis of gastroesophageal reflux. (HealthDay News) — For patients with type 2 diabetes, there is an association between glucagon-like ...

Those prescribed a GLP-1 RA had a significantly increased risk for new chronic cough compared with those prescribed any non-GLP-1 RA second-line medication, DPP-4 inhibitor, or sulfonylurea in a ...